Art. -Nr.: HY-N0644

Carnosic acid

10 Cited Publications

Kundenbewertung

Based on 10 publication(s) in Google Scholar

Carnosic acid is an orally active lipid absorption inhibitor. Carnosic acid has demonstrated inhibition of oxidative stress and inflammation, suppression of cell proliferation, and antibacterial activity.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 98.08%
CAS. Nr.: 3650-09-7
Formel: C₂₀H₂₈O₄
Molecular Weight:332.43

Speicherung:

-80°C, stored under nitrogen

Carnosic acid Chemical Structure

CAS. Nr.: 3650-09-7

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- Cellular Effect
- In Vitro
Chemical Information
Publications (10)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	5 μM Compound: 8	Inhibition of microsomal PGES1 in ILbeta-stimulated human A549 cells using PGH2 as substrate preincubated for 15 mins followed by substrate addition measured after 1 min by RP-HPLC analysis Inhibition of microsomal PGES1 in ILbeta-stimulated human A549 cells using PGH2 as substrate preincubated for 15 mins followed by substrate addition measured after 1 min by RP-HPLC analysis	10.1039/C5MD00278H
AGS	IC₅₀	89.8 μM Compound: 1	Cytotoxicity against human AGS cells after 24 hrs by neutral red uptake assay Cytotoxicity against human AGS cells after 24 hrs by neutral red uptake assay	[PMID: 20359186]
Hepatocyte	EC₅₀	94.8 μM Compound: CA, Carnosic acid	Cytotoxicity against human hepatocytes assessed as reduction in cell viability after 24 hrs by ATP detection based assay Cytotoxicity against human hepatocytes assessed as reduction in cell viability after 24 hrs by ATP detection based assay	[PMID: 22531045]
Hepatocyte	EC₅₀	95.7 μM Compound: CA, Carnosic acid	Cytotoxicity against human hepatocytes assessed as reduction in cell viability after 4 hrs by ATP detection based assay Cytotoxicity against human hepatocytes assessed as reduction in cell viability after 4 hrs by ATP detection based assay	[PMID: 22531045]
HepG2	IC₅₀	41.3 μM Compound: 1	Cytotoxicity against human HepG2 cells after 24 hrs by neutral red uptake assay Cytotoxicity against human HepG2 cells after 24 hrs by neutral red uptake assay	[PMID: 20359186]
MIA PaCa-2	EC₅₀	5.5 μM Compound: CA	Cytotoxicity against human MIAPaCa2 cells assessed as decrease in cell growth measured after 72 hrs by MTT assay Cytotoxicity against human MIAPaCa2 cells assessed as decrease in cell growth measured after 72 hrs by MTT assay	[PMID: 31725297]
MRC5	IC₅₀	21.8 μM Compound: 1	Cytotoxicity against human MRC5 cells after 24 hrs by neutral red uptake assay Cytotoxicity against human MRC5 cells after 24 hrs by neutral red uptake assay	[PMID: 20359186]
PANC-1	EC₅₀	150 μM Compound: CA	Cytotoxicity against human PANC1 cells assessed as decrease in cell growth measured after 72 hrs by MTT assay Cytotoxicity against human PANC1 cells assessed as decrease in cell growth measured after 72 hrs by MTT assay	[PMID: 31725297]

In Vitro

Carnosic acid, a phenolic diterpene, is enriched in the leaves of Lamiaceae plants, and is particularly high in dried leaves of Rosmarinus officinalis L. and Salvia officinalis. Carnosic acid has demonstrated inhibition of oxidative stress and inflammation, suppression of cell proliferation, and antibacterial activity. It is widely reported that Carnosic acid has a therapeutic potential in different types of cancer, mostly based on in vitro experiments. Carnosic acid has also shown neuroprotective effects in experimental models of neurodegenerative diseases, mainly through activation of the antioxidant NRF2/ARE pathway^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS. Nr. 3650-09-7
Appearance Solid
Molecular Weight 332.43
Formel C₂₀H₂₈O₄
Color White to light yellow
SMILES

OC([C@@]([C@@]1([H])CCC2=CC(C(C)C)=C3O)(CCCC1(C)C)C2=C3O)=O
Structure Classification
- Terpenoids
- Diterpenoids
- Phenols
- Polyphenols
Initial Source
- Plants
- Labiatae
Versand

Shipping with dry ice.
Speicherung

-80°C, stored under nitrogen

Publications (10)

All Cell Proliferation/Viability AssayWBCell Imaging/StainingFlow Cytometry

Sort by:

Journal Impact Factor

Adv Sci (Weinh)

Multi-Targeting Carnosic Acid Kills Drug-Resistant Helicobacter pylori With Narrow-Spectrum Activity. [Abstract]

2026 Jun 11:e76080. PMID: 42272345
PLoS Biol

A high-throughput behavioral screening platform for measuring chemotaxis by C. elegans. [Abstract]

2024 Jun 27;22(6):e3002672. PMID: 38935621
Nutrients

Inhibition of Prostate Cancer Cell Survival and Proliferation by Carnosic Acid Is Associated with Inhibition of Akt and Activation of AMPK Signaling. [Abstract]

2024 Apr 24;16(9):1257. PMID: 38732504

Carnosic acid purchased from MedChemExpress. Usage Cited in: Nutrients. 2024 Apr 24;16(9):1257. [Abstract]

Carnosic acid (CA) dose-dependently Inhibits prostate cancer cell survival. PC-3 prostate cancer cells were treated without (Control) or with the indicated concentrations of Carnosic acid (CA) for 7 days followed by staining with methylene blue and colony counting.

Carnosic acid purchased from MedChemExpress. Usage Cited in: Nutrients. 2024 Apr 24;16(9):1257. [Abstract]

Carnosic acid (CA, 70 μM) inhibited Akt. PC-3 cells were treated without (Control) or with the indicated concentrations of CA or DTX for 24 or 48 h followed by whole cell lysate preparation and total protein yield assessment. Lysates (20 µg of protein) were resolved by SDS-PAGE and immunoblotted with specific antibodies against total or phosphorylated Akt (Ser473) or β-actin.
Eur J Pharmacol

Carnosic acid protects against mitochondrial dysfunction and ferroptosis in myocardial ischemia/reperfusion injury through mediating Mfn2. [Abstract]

2026 Mar 28:1019:178690. PMID: 41765272

Carnosic acid purchased from MedChemExpress. Usage Cited in: Eur J Pharmacol. 2026 Mar 28:1019:178690. [Abstract]

CCK-8 was used to assess the viability of A/R-induced H9c2 cells treated with different concentrations of Carnosic acid (CA) (1.25–40 μM; 48 h). The cell viability of H9c2 cells treated by anoxic/reoxygenation (A/R) was reversed after CA pretreatment at different concentrations.

Carnosic acid purchased from MedChemExpress. Usage Cited in: Eur J Pharmacol. 2026 Mar 28:1019:178690. [Abstract]

The apoptotic rate was measured using Annexin V-FITC/PI detected by flow cytometry. H9c2 cells in the CA + A/R group were treated with 10 μM CA for 48 h H9c2 cells in the er-1 + A/R group were pretreated with 10 μM Fer-1 for 2 h. CA, Carnosic acid; A/R, anoxic/reoxygenation; Fer-1, ferrostatin-1.

Carnosic acid purchased from MedChemExpress. Usage Cited in: Eur J Pharmacol. 2026 Mar 28:1019:178690. [Abstract]

Western blots were used to analyze the expression of ferroptosis-related proteins and Mfn2 in A/R-induced cells after Carnosic acid (CA) or Fer-1 pretreatment. H9c2 cells in the CA + A/R group were treated with 10 μM CA for 48 h; H9c2 cells in the Fer-1 + A/R group were pretreated with 10 μM Fer-1 for 2 h. The protein level of PTGS2 was higher, and that of GPX4 was lower in the A/R group than in the control group. However, pretreatment with CA and Fer-1 prevented these changes.

Carnosic acid purchased from MedChemExpress. Usage Cited in: Eur J Pharmacol. 2026 Mar 28:1019:178690. [Abstract]

DCFH-DA-stained images for the detection of ROS (magnification, x400; scale bar, 20 μm). H9c2 cells in the CA + A/R group were treated with 10 μM CA for 48 h H9c2 cells in the Fer-1 + A/R group were pretreated with 10 μM Fer-1 for 2 h. CA, Carnosic acid; A/R, anoxic/reoxygenation; Fer-1, ferrpstatin-1.
Int J Mol Sci

Carnosic Acid against Lung Cancer: Induction of Autophagy and Activation of Sestrin-2/LKB1/AMPK Signalling. [Abstract]

2024 Feb 6;25(4):1950. PMID: 38396629

Carnosic acid purchased from MedChemExpress. Usage Cited in: Int J Mol Sci. 2024 Feb 6;25(4):1950. [Abstract]

Carnosic acid (CA) caused concentration- and time-dependent inhibition of H1299 cell proliferation with an IC₅₀ of 47.3 µM and 27.1 µM for 24 h and 48 h, respectively.

Carnosic acid purchased from MedChemExpress. Usage Cited in: Int J Mol Sci. 2024 Feb 6;25(4):1950. [Abstract]

Carnosic acid (CA) induced apoptosis of H1299 NSCLC cells. H1299 cells were treated for 24 h with 5 nM paclitaxel (PTX), 25 µM CA, or 50 µM CA, and nuclear morphology was assessed qualitatively using Hoechst 33342 and a BioTek Cytation 5 plate reader. CA-treated cells had noticeably smaller nuclei, which was consistent with the nuclear condensation that occurred during apoptosis.
Hum Mol Genet

Carnosol, a diterpene present in rosemary, increases ELP1 levels in familial Dysautonomia (FD) patient-derived cells and healthy adults: a possible therapy for FD. [Abstract]

2022 Oct 10;31(20):3521-3538. PMID: 35708500
Hereditas

Carnosic acid enhances cisplatin sensitivity and suppresses gastric cancer progression via the TP53/SLC7A11/ALOX12 axis. [Abstract]

2025 Jul 23;162(1):139. PMID: 40696490
SSRN

2026 May 19.
SSRN

2025 Aug 26.
bioRxiv

An efficient behavioral screening platform classifies natural products and other chemical cues according to their chemosensory valence in C. elegans. [Abstract]

2024 Apr 3:2023.06.02.542933. PMID: 37333363

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 130 mg/mL (391.06 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.0082 mL

15.0408 mL

30.0815 mL

5 mM

0.6016 mL

3.0082 mL

6.0163 mL

10 mM

0.3008 mL

1.5041 mL

3.0082 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months (stored under nitrogen). When stored at -80°C, please use it within 6 months.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (7.52 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: 2.08 mg/mL (6.26 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 2.08 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.08 mg/mL (6.26 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (279 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Yesil-Celiktas O, et al. Inhibitory effects of rosemary extracts, carnosic acid and rosmarinic acid on the growth of various human cancer cell lines. Plant Foods Hum Nutr. 2010 Jun;65(2):158-63. [Content Brief]

[2]. Kiyofumi Ninomiya, et al. Carnosic acid, a new class of lipid absorption inhibitor from sage. Bioorg Med Chem Lett. 2004 Apr 19;14(8):1943-6. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months (stored under nitrogen). When stored at -80°C, please use it within 6 months.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	3.0082 mL	15.0408 mL	30.0815 mL	75.2038 mL
	5 mM	0.6016 mL	3.0082 mL	6.0163 mL	15.0408 mL
	10 mM	0.3008 mL	1.5041 mL	3.0082 mL	7.5204 mL
	15 mM	0.2005 mL	1.0027 mL	2.0054 mL	5.0136 mL
	20 mM	0.1504 mL	0.7520 mL	1.5041 mL	3.7602 mL
	25 mM	0.1203 mL	0.6016 mL	1.2033 mL	3.0082 mL
	30 mM	0.1003 mL	0.5014 mL	1.0027 mL	2.5068 mL
	40 mM	0.0752 mL	0.3760 mL	0.7520 mL	1.8801 mL
	50 mM	0.0602 mL	0.3008 mL	0.6016 mL	1.5041 mL
	60 mM	0.0501 mL	0.2507 mL	0.5014 mL	1.2534 mL
	80 mM	0.0376 mL	0.1880 mL	0.3760 mL	0.9400 mL
	100 mM	0.0301 mL	0.1504 mL	0.3008 mL	0.7520 mL

Keywords

Carnosic acid

10 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Carnosic acid

Natural Product Library Plus

Cosmetic Ingredient Compound Library

Publications Citing Use of MedChemExpress (MCE) Carnosic acid

Biologische Aktivität

Chemical Information

Publications (10)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Carnosic acid

Natural Product Library Plus

Cosmetic Ingredient Compound Library

Publications Citing Use of MedChemExpress (MCE) Carnosic acid

Biologische Aktivität

Chemical Information

Publications (10)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Carnosic acid Related Classifications

HY-N0644 Related Classifications